NewAmsterdam Pharma Co Stock (NASDAQ: NAMS)

NewAmsterdam Pharma Co

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACEL

CART

CDNA

FLYW

LBTYK

LMND

NAMS

SGRY

ZETA

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

AAMI

AXON

CLIK

ENVB

HCTI

ICCT

PITA

PRCH

SMCI

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Portland,,Oregon,-may,11,2019:,Southwest,Airlines,Passenger,Planes,At

ANIP

CFFI

RLGT

SIBN

SLXN

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

NamSys Inc

Press Releases

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Earnings

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Health Care

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Analyst Ratings

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NAMSW

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

CG Oncology

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Needham

Scotiabank

RBC Capital

HC Wainwright & Co.

Comments

NewAmsterdam Pharma Co

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell